Company ASP Isotopes Inc.

ASPI

US00218A1051

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals

End-of-day quote Nasdaq Other stock markets 03:30:00 23/05/2024 am IST			5-day change	1st Jan Change
5.03 ^USD	-1.18%		+11.28%	+181.01%

15/05	ASP Isotopes Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
10/04	ASP Isotopes Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ASP Isotopes Inc. is a pre-commercial stage advanced materials company. The Company is engaged in the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (ASP technology). Its initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. Its Nuclear Fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment is focused on research and development of technologies and methods used to separate high-value, low-volume isotopes (such as C-14, Mo-100 and Si-28) for highly specialized target end markets other than advanced nuclear fuels, including pharmaceuticals and agrochemicals, nuclear medical imaging, and others.

Number of employees: 76

USD in Million	2022	Weight	2023	Weight	Delta
Specialist Isotopes and Related Services 100.0 %	0	nan %	0	100.0 %	-

USD in Million	2022	Weight	2023	Weight	Delta
United States, Guernsey, South Africa and United Kingdom 100.0 %	0	nan %	0	100.0 %	-

Managers	Title	Age	Since
Robert Ainscow FOU	Founder	48	13/21/13
Paul Mann CEO	Chief Executive Officer	48	13/21/13
Hendrik Strydom CTO	Chief Tech/Sci/R&D Officer	64	01/22/01

Members of the board	Title	Age	Since
Duncan Moore BRD	Director/Board Member	65	01/21/01
Paul Mann CEO	Chief Executive Officer	48	13/21/13
Todd Wider BRD	Director/Board Member	59	01/21/01
Hendrik Strydom CTO	Chief Tech/Sci/R&D Officer	64	01/22/01
Mike Gorley BRD	Director/Board Member	37	19/23/19
Rob Ryan BRD	Director/Board Member	55	14/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	51,762,833	26,857,768 ( 51.89 %)	0	51.89 %

Name	Equities	%	Valuation
A.K. Jensen Investment Management Ltd. 13.32 %	6,516,874	13.32 %	22 M $
Paul Mann 12.30 %	6,018,277	12.30 %	20 M $
Sergey Vasnetsov 7.846 %	3,838,607	7.846 %	13 M $
Hendrik Strydom 4.811 %	2,353,772	4.811 %	8 M $
Einar Ronander 4.287 %	2,097,424	4.287 %	7 M $
Rapp Rapoport 3.250 %	1,590,000	3.250 %	5 M $
Vanguard Global Advisers LLC 2.087 %	1,021,019	2.087 %	3 M $
Robert Ainscow 1.965 %	961,373	1.965 %	3 M $
Duncan Moore 1.746 %	854,167	1.746 %	3 M $
Rob Ryan 1.169 %	572,102	1.169 %	2 M $

ASP Isotopes, Inc.

1101 Pennsylvania Avenue Northwest Suite 300

20004, Washington

http://www.aspisotopes.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.43 USD

Average target price

5.5 USD

Spread / Average Target

+1.29%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
ASP ISOTOPES INC.	+181.01%	28Cr
ELI LILLY AND COMPANY	+38.51%	73TCr
NOVO NORDISK A/S	+33.05%	60TCr
JOHNSON & JOHNSON	-6.23%	35TCr
MERCK & CO., INC.	+18.78%	33TCr
ABBVIE INC.	+1.35%	28TCr
ASTRAZENECA PLC	+16.00%	24TCr
NOVARTIS AG	+8.09%	20TCr
ROCHE HOLDING AG	-5.77%	20TCr
AMGEN INC.	+6.19%	16TCr

Other Pharmaceuticals